Sequence type 17 is a predictor of subsequent bacteremia in vancomycin-resistant Enterococcus faecium-colonized patients: a retrospective cohort study.
Colonization
Genotype
Microbial drug resistance
Multilocus sequence typing
Risk factors
Journal
Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411
Informations de publication
Date de publication:
22 07 2021
22 07 2021
Historique:
received:
03
05
2021
accepted:
13
07
2021
entrez:
23
7
2021
pubmed:
24
7
2021
medline:
27
1
2022
Statut:
epublish
Résumé
Sequence type (ST) 17 vancomycin-resistant Enterococcus faecium (VREF) is frequently isolated in nosocomial settings. The aim of this study was to identify whether ST17 contributes to subsequent bacteremia more often than other STs among hospitalized patients carrying VREF. A retrospective cohort study was conducted in patients carrying ST17 VREF and those with non-ST17 VREF. Rectal screening according to hospital policy was used to identify patients with VREF. Subsequent VREF bacteremia events within a year of detection of colonization were recorded. Cox regression analysis was used to adjust the covariates involved in determining the association between ST17 and subsequent bacteremia events. The cohorts comprised 52 patients with ST17 and 169 patients with non-ST17 VREF. One-year VREF bacteremia-free rates were 85.9% and 90.2%, respectively. In multivariate analysis, ST17 was associated with subsequent bacteremia at an adjusted hazard risk (aHR) of 4.02 (95% confidence interval [CI], 1.32-12.29). Liver transplantation (aHR, 40.08; 95% CI, 4.87-329.76) and hematologic malignancy (aHR, 20.97; 95% CI, 4.87-87.82) were also significant. All cases of subsequent bacteremia in ST17 VREF carriers were caused by ST17; however, subsequent bacteremia in non-ST17 carriers was often caused by ST17 or another ST variant. A specific genotype, ST17 is a predictor of subsequent bacteremia in hospitalized patients carrying VREF. Patients with a hematologic malignancy and those receiving a liver transplant are also at high risk. More targeted strategies may be needed to prevent VREF infection in hospitals.
Sections du résumé
BACKGROUND
Sequence type (ST) 17 vancomycin-resistant Enterococcus faecium (VREF) is frequently isolated in nosocomial settings. The aim of this study was to identify whether ST17 contributes to subsequent bacteremia more often than other STs among hospitalized patients carrying VREF.
METHODS
A retrospective cohort study was conducted in patients carrying ST17 VREF and those with non-ST17 VREF. Rectal screening according to hospital policy was used to identify patients with VREF. Subsequent VREF bacteremia events within a year of detection of colonization were recorded. Cox regression analysis was used to adjust the covariates involved in determining the association between ST17 and subsequent bacteremia events.
RESULTS
The cohorts comprised 52 patients with ST17 and 169 patients with non-ST17 VREF. One-year VREF bacteremia-free rates were 85.9% and 90.2%, respectively. In multivariate analysis, ST17 was associated with subsequent bacteremia at an adjusted hazard risk (aHR) of 4.02 (95% confidence interval [CI], 1.32-12.29). Liver transplantation (aHR, 40.08; 95% CI, 4.87-329.76) and hematologic malignancy (aHR, 20.97; 95% CI, 4.87-87.82) were also significant. All cases of subsequent bacteremia in ST17 VREF carriers were caused by ST17; however, subsequent bacteremia in non-ST17 carriers was often caused by ST17 or another ST variant.
CONCLUSIONS
A specific genotype, ST17 is a predictor of subsequent bacteremia in hospitalized patients carrying VREF. Patients with a hematologic malignancy and those receiving a liver transplant are also at high risk. More targeted strategies may be needed to prevent VREF infection in hospitals.
Identifiants
pubmed: 34294150
doi: 10.1186/s13756-021-00980-1
pii: 10.1186/s13756-021-00980-1
pmc: PMC8299594
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108Informations de copyright
© 2021. The Author(s).
Références
Am J Infect Control. 2008 Dec;36(10):S175.e5-8
pubmed: 19084155
J Infect Dis. 2003 Feb 1;187(3):508-12
pubmed: 12552437
Emerg Infect Dis. 2005 Jun;11(6):821-8
pubmed: 15963275
Lancet. 2001 Mar 17;357(9259):853-5
pubmed: 11265956
Am J Infect Control. 2016 May 1;44(5):515-9
pubmed: 26781220
J Bacteriol. 2004 Mar;186(5):1518-30
pubmed: 14973027
Infect Control Hosp Epidemiol. 2016 Nov;37(11):1288-1301
pubmed: 27573805
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
J Clin Microbiol. 2004 Oct;42(10):4473-9
pubmed: 15472296
Clin Infect Dis. 2002 Nov 15;35(10):1139-46
pubmed: 12410472
Am J Infect Control. 2006 Oct;34(8):534-6
pubmed: 17015161
PLoS One. 2014 Dec 30;9(12):e115555
pubmed: 25549328
Enferm Infecc Microbiol Clin (Engl Ed). 2018 Mar;36(3):198-200
pubmed: 28807390
Clin Infect Dis. 2017 Jun 15;64(12):1753-1759
pubmed: 28369204
J Antimicrob Chemother. 2009 Jan;63(1):17-20
pubmed: 19001448
Eur J Clin Microbiol Infect Dis. 2005 Dec;24(12):815-25
pubmed: 16374593
J Antimicrob Chemother. 2012 Apr;67(4):832-6
pubmed: 22228676
J Clin Microbiol. 2002 Jun;40(6):1963-71
pubmed: 12037049
FEMS Immunol Med Microbiol. 2008 Apr;52(3):297-308
pubmed: 18279340
Mayo Clin Proc. 2006 Apr;81(4):529-36
pubmed: 16610573
Diagn Microbiol Infect Dis. 2013 Aug;76(4):477-82
pubmed: 23721721
Lancet Infect Dis. 2001 Dec;1(5):314-25
pubmed: 11871804
Infect Control Hosp Epidemiol. 2008 May;29(5):404-9
pubmed: 18419361
Clin Infect Dis. 2006 Jan 15;42(2):195-203
pubmed: 16355329
Antimicrob Agents Chemother. 1994 Jun;38(6):1363-7
pubmed: 8092838
Infect Control Hosp Epidemiol. 2017 Feb;38(2):203-215
pubmed: 27825401
Medicine (Baltimore). 1988 Jul;67(4):248-69
pubmed: 3134590